Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Chang

Showing results (231-240 of 386) with videos related to

Pageof 39
Sort By:
Neuro-Oncology Practice|September 27, 2019
Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survivalChristopher H Chapman, Jared H Hara, Annette M Molinaro, et al.
Lancet (London, England)|September 28, 2011
Inequality in early childhood: risk and protective factors for early child developmentSusan P Walker, Theodore D Wachs, Sally Grantham-McGregor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2017
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILEBrian M Alexander, Sujuan Ba, Mitchel S Berger, et al.
Neuro-Oncology|April 25, 2020
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatmentRaymond Y Huang, Robert J Young, Benjamin M Ellingson, et al.
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2017
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomaJennifer L Clarke, Annette M Molinaro, Juan R Cabrera, et al.
JCI Insight|November 3, 2018
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MRSpencer C Behr, Javier E Villanueva-Meyer, Yan Li, et al.
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Pageof 39

Showing results (231-240 of 386) with videos related to

Sort By:
Pageof 39
Neuro-Oncology Practice|September 27, 2019
Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survivalChristopher H Chapman, Jared H Hara, Annette M Molinaro, et al.
Lancet (London, England)|September 28, 2011
Inequality in early childhood: risk and protective factors for early child developmentSusan P Walker, Theodore D Wachs, Sally Grantham-McGregor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2017
Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILEBrian M Alexander, Sujuan Ba, Mitchel S Berger, et al.
Neuro-Oncology|April 25, 2020
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatmentRaymond Y Huang, Robert J Young, Benjamin M Ellingson, et al.
The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2017
A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade gliomaJennifer L Clarke, Annette M Molinaro, Juan R Cabrera, et al.
JCI Insight|November 3, 2018
Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MRSpencer C Behr, Javier E Villanueva-Meyer, Yan Li, et al.
Neuro-Oncology|October 15, 2014
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)Patrick Y Wen, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology|January 8, 2023
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survivalBenjamin M Ellingson, Patrick Y Wen, Susan M Chang, et al.
Pageof 39